Table 1.
Baseline characteristics of the study population
| Frequency no (%) | ||
|---|---|---|
| Study Area | Buea | 87 (43.5 %) |
| Limbe | 62 (31.0) | |
| Kumba | 51 (25.5) | |
| Total | 200 (100) | |
| Gender | Male | 101 (50.5) |
| Female | 99 (49.5) | |
| Total | 200 (100) | |
| Age group (years) mean = 38.04 ± 10.52 years | ||
| 21–30 | 55 (27.5) | |
| 31–40 | 76 (38.0) | |
| 41–50 | 43 (21.5) | |
| ≥51 | 26 (13.0) | |
| Total | 200 (100) | |
| Education level | No formal education | 12 (6.0) |
| Primary | 87 (43.5) | |
| Secondary | 74 (37.0) | |
| Tertiary | 27 (13.0) | |
| Total | 200 (100) | |
| eGFR (ml/min/1.73 m2) | <60 | 16 (8.0) |
| ≥60 | 184 (92.0) | |
| Total | 200 (100) | |
| Treatment groups | HAART | 70 (35.0) |
| DOTS | 70 (35.0) | |
| HAART/ DOTS | 60 (30.0) | |
| Total | 200 (100) | |
| Type of HAART | AZT/3TC/NVP | 46 (65.7) |
| 1 HAART group (n = 70) | AZT/3TC/EVP | 3 (4.3) |
| TNV/3TC/NVP | 21 (30.0) | |
| 2 HAART/DOTS group (n = 60) | AZT/3TC/NVP | 34 (56.7) |
| AZT/3TC/EVP | 3 (5.0) | |
| TNV/3TC/NVP | 23 (38.3) | |
| Total | 130 (65) | |
| Type of DOTS | ||
| 1 DOTS group (n = 70) | ||
| RIF/INH/ETH/PZA | 38 (54.3) | |
| RIF/INH | 32 (45.7) | |
| 2 HAART/DOTS group (n = 60) | RIF/INH/ETH/PZA | 25 (41.7) |
| RIF/INH | 35 (58.3) | |
| Total | 130 (65) |
Key: AZT/3TC/NVP Zidovudine, Lamivudine, Nevirapine, AZT/3TC/EFV Zidovudine, Lamivudine, Efavirenz, TDF/3TC/EFV Tenofovir, Lamivudine, Efavirenz, HAART Highly Active Antiretroviral Therapy, DOTS Direct Observed Therapy, Short-course, RIF/INH/ETH/PZA rifamycin, isoniazid, ethambutol, pyrazinamide, RIF/INH rifamycin, isoniazid